Distinct Trajectories of Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Survivors Treated With R-CHOP

To explore the trajectories of chemotherapy-induced peripheral neuropathy (CIPN) in lymphoma survivors and assess subdomains of CIPN in this population.

80 newly diagnosed lymphoma survivors treated with R-CHOP were enrolled.

CIPN was assessed before chemotherapy (T1), after the first chemotherapy cycle (T2), after the fourth chemotherapy cycle (T3), after the completion of chemotherapy (T4), and 10 weeks post-treatment (T5). CIPN was measured using the Total Neuropathy Score clinical version and the MD Anderson Symptom Inventory.

Patients were categorized into high and low CIPN groups based on CIPN changes over time. The high CIPN group was older and experienced significantly more severe sensory peripheral neuropathy from T1 to T5, with the most severe symptoms observed at T4, followed by T3 and T5.

Healthcare providers should closely monitor older patients, those with pretreatment peripheral neuropathy symptoms, and those exhibiting pronounced sensory neuropathy during treatment to provide timely and effective symptom management, reducing the impact of CIPN.